AcquisitionsNov 5, 2026, 05:02 PM
iSpecimen Acquires AI Products from Foldlab AI for $4.5M
AI Summary
iSpecimen Inc. has completed the acquisition of two artificial intelligence products from Foldlab AI Ltd. for an aggregate purchase price of $4.5 million. The acquisition includes AI software, models, source code, data rights, and intellectual property related to disease-associated protein discovery and disease trend prediction. The purchase price consists of $750,000 in cash, up to $1.25 million in milestone payments, and $2.5 million in iSpecimen's common stock (2,907,977 shares). The stock consideration is subject to a five-year lock-up agreement. This acquisition marks iSpecimen's expansion into AI-powered disease intelligence, complementing its existing biospecimen marketplace.
Key Highlights
- iSpecimen Inc. acquired Foldlab AI Ltd.'s AI products for $4.5 million.
- Purchase price includes $750,000 cash, up to $1.25 million in milestone payments, and $2.5 million in company stock.
- Acquired assets include AI software, models, source code, data rights, and intellectual property for disease-associated protein discovery and disease trend prediction.
- The company issued 2,907,977 shares of common stock as part of the stock consideration.
- The stock consideration is subject to a five-year lock-up period with no leak-out provisions.
- An amendment to the Asset Purchase Agreement modified the terms regarding stock consideration escrow and voting rights.
Price Impact
More from ISPC